{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:54:37Z","timestamp":1787064877126,"version":"build-2736575974"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aim<\/jats:title>\n                    <jats:p>The effects of vedolizumab [VEDO] exposure on perioperative outcomes following surgery for inflammatory bowel disease [IBD] remain controversial. The aim of our study was to compare postoperative morbidity of IBD surgery following treatment with VEDO vs other biologics or no biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An institutional review board-approved, prospectively collected database was queried to identify all patients undergoing abdominal surgery for IBD between August 2012 and May 2017. The impact of VEDO within 12 weeks preoperatively on postoperative morbidity was initially assessed with univariate and multivariable analyses on all patients. A case-matched analysis was then carried out comparing patients exposed to VEDO vs other biologic agents, based on gender, age \u00b1 5 years, diagnosis, date of surgery \u00b1 2 years, and surgical procedure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 980 patients, 141 received VEDO. The majority of patients [59%] underwent surgery involving end or diverting ostomy creation. The initial multivariate analysis conducted on all patients indicated that VEDO use was independently associated with increased overall morbidity [p &amp;lt;0.001], but not infectious morbidity [p = 0.30]. However, the case-matched comparison of 95 VEDO-treated patients vs 95 patients treated with adalimumab or infliximab did not indicate any difference in overall morbidity [p = 0.32], infectious complications [p = 0.15], or surgical site infections [p = 0.12].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a study population having a high rate of surgery involving ostomy creation, the exposure to preoperative VEDO was not associated with an increased morbidity rate when compared with other biologics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjz129","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T01:00:02Z","timestamp":1563757202000},"page":"185-191","source":"Crossref","is-referenced-by-count":20,"title":["Case-matched Comparison of Postoperative Outcomes Following Surgery for Inflammatory Bowel Disease After Exposure to Vedolizumab vs Other Biologics"],"prefix":"10.1093","volume":"14","author":[{"given":"M","family":"Novello","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Stocchi","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S R","family":"Steele","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2549-9042","authenticated-orcid":false,"given":"S D","family":"Holubar","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L C","family":"Duraes","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kessler","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Shawki","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L T","family":"Hull","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,20]]},"reference":[{"key":"2020042909255664700_CIT0001","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2020042909255664700_CIT0002","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2020042909255664700_CIT0003","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2020042909255664700_CIT0004","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"2020042909255664700_CIT0005","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1097\/MIB.0000000000000561","article-title":"Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort","volume":"21","author":"Shelton","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2020042909255664700_CIT0006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/ecco-jcc\/jjw147","article-title":"Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease","volume":"11","author":"Lightner","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2020042909255664700_CIT0007","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/ajg.2017.201","article-title":"Risk of postoperative complications among inflammatory bowel disease patients treated preoperatively with vedolizumab","volume":"112","author":"Yamada","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2020042909255664700_CIT0008","author":"Centers for Disease Control and Prevention National Healthcare Safety Network"},{"key":"2020042909255664700_CIT0009","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/501620","article-title":"Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee","volume":"20","author":"Mangram","year":"1999","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020042909255664700_CIT0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00464-013-3218-7","article-title":"Total abdominal colectomy for severe ulcerative colitis: does the laparoscopic approach really have benefit?","volume":"28","author":"Gu","year":"2014","journal-title":"Surg Endosc"},{"key":"2020042909255664700_CIT0011","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10151-017-1667-z","article-title":"Factors associated with hospital readmission following diverting ileostomy creation","volume":"21","author":"Li","year":"2017","journal-title":"Tech Coloproctol"},{"key":"2020042909255664700_CIT0012","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ecco-jcc\/jjy022","article-title":"Systematic review and meta-analysis: preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease","volume":"12","author":"Law","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2020042909255664700_CIT0013","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/ibd\/izx076","article-title":"Postoperative outcomes in vedolizumab-treated patients undergoing major abdominal operations for inflammatory bowel disease: retrospective multicenter cohort study","volume":"24","author":"Lightner","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2020042909255664700_CIT0014","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/ecco-jcc\/jjx095","article-title":"Perioperative use of vedolizumab is not associated with postoperative infectious complications in patients with ulcerative colitis undergoing colectomy","volume":"11","author":"Ferrante","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2020042909255664700_CIT0015","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1097\/MIB.0000000000001248","article-title":"Surgical outcomes in vedolizumab-treated patients with ulcerative colitis","volume":"23","author":"Lightner","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2020042909255664700_CIT0016","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/apt.14459","article-title":"Postoperative outcomes in vedolizumab-treated Crohn\u2019s disease patients undergoing major abdominal operations","volume":"47","author":"Lightner","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2020042909255664700_CIT0017","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/apt.14842","article-title":"Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease","volume":"48","author":"Park","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2020042909255664700_CIT0018","doi-asserted-by":"crossref","unstructured":"Cohen\n              BL\n            , FleshnerP, KaneSV, et al\n          Anti-tumor necrosis factor therapy is not associated with post-operative infection: results from prospective cohort of ulcerative colitis and Crohn\u2019s disease patients undergoing surgery to identify risk factors for postoperative infection I (PUCCINI). Gastroenterology2019;156:S\u201380.","DOI":"10.1016\/S0016-5085(19)36987-2"},{"key":"2020042909255664700_CIT0019","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1007\/s11605-008-0646-0","article-title":"Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn\u2019s patients","volume":"12","author":"Appau","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"2020042909255664700_CIT0020","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/DCR.0b013e3182a0e702","article-title":"Operative strategy modifies risk of pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor-\u03b1 therapy","volume":"56","author":"Gu","year":"2013","journal-title":"Dis Colon Rectum"},{"key":"2020042909255664700_CIT0021","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/SLA.0000000000000757","article-title":"The impact of preoperative serum anti-TNF\u03b1 therapy levels on early postoperative outcomes in inflammatory bowel disease surgery","volume":"261","author":"Lau","year":"2015","journal-title":"Ann Surg"},{"key":"2020042909255664700_CIT0022","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/ecco-jcc\/jjx021","article-title":"Exposure-efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn\u2019s disease","volume":"11","author":"Rosario","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2020042909255664700_CIT0023","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/apt.12869","article-title":"Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn\u2019s disease","volume":"40","author":"Mazor","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2020042909255664700_CIT0024","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjz129\/29091915\/jjz129.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/2\/185\/32399972\/jjz129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/2\/185\/32399972\/jjz129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T09:26:15Z","timestamp":1588152375000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/2\/185\/5536704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,20]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,7,20]]},"published-print":{"date-parts":[[2020,2,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz129","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2019,7,20]]}}}